Evolocumab

Evidence Level: L5

Predicted Indications: 10

Evolocumab
Evolocumab: From Homozygous Familial Hypercholesterolemia to Symptomatic Hemophilia in Female Carriers

## Pharmacist Assessment Report

Evolocumab: From Homozygous Familial Hypercholesterolemia to Symptomatic Hemophilia in Female Carriers

One-Sentence Summary

Evolocumab is a PCSK9-inhibiting antibody, originally used for lipid disorders such as homozygous familial hypercholesterolemia. The TxGNN model predicts it may be effective for symptomatic form of hemophilia in female carriers, with a very high score. However, no clinical trials and no publications currently support this direction, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Homozygous familial hypercholesterolemia; syndromic dyslipidemia (from the knowledge graph, since the registered indication text is empty)
Predicted New Indication	Symptomatic form of hemophilia in female carriers
TxGNN Prediction Score	99.82%
Evidence Level	L5
Singapore Market Status	✓ Marketed
Number of Registrations	2
Recommended Decision	Hold

Why is This Prediction Reasonable?

Evolocumab is a monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). By blocking PCSK9, it increases the availability of LDL receptors and lowers LDL cholesterol. Detailed mechanism-of-action data were not available in the data compiled for this report, but the target (PCSK9) is documented.

The predicted condition is a different kind of disease. Symptomatic hemophilia in female carriers arises from reduced factor VIII or IX activity due to X-linked variants. This pathway is unrelated to PCSK9 or LDL metabolism, and no plausible mechanistic link was identified. The high score (0.998) reflects proximity in the knowledge graph, not biological rationale or clinical data.

Other top-ranked predictions show the same pattern. Examples include familial apolipoprotein C-II deficiency, thrombocytopenic purpura and factor XI deficiency. Most are coagulation or rare metabolic disorders with no mechanistic connection to PCSK9 inhibition. Familial apolipoprotein C-II deficiency has only indirect plausibility, because it is a lipid disorder, but evolocumab is unlikely to correct its lipase activation defect.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN15223P	REPATHA Solution for Injection in Pre-filled Syringe 140mg/mL	Injection, solution	Not stated in the data compiled
SIN15224P	REPATHA Solution for Injection in Pre-filled Autoinjector 140mg/mL	Injection, solution	Not stated in the data compiled

Both licences are valid single-ingredient products from Amgen Manufacturing Limited LLC.

Safety Considerations

Drug Interactions: Only a pharmacology entry for the target (PCSK9) was found. No drug-drug interactions with specific medicines were identified.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a knowledge-graph score. There are no trials or publications, and no plausible mechanistic link between PCSK9 inhibition and the clotting-factor deficiency in hemophilia carriers. The other nine top-ranked predictions are likewise L5 and similarly unsupported.

To proceed, the following is needed:

Package insert warnings and contraindications from HSA, which are required for safety screening
Detailed mechanism-of-action data
Any mechanistic or preclinical rationale linking PCSK9 inhibition to factor VIII/IX deficiency
A review of whether a better-supported indication exists among the other predictions, or within the lipid disorders already established for this drug
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.